OncoMatch/Clinical Trials/NCT05768035
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Is NCT05768035 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Allogeneic T cell progenitors, cultured ex-vivo for hematological malignancies.
Treatment: Allogeneic T cell progenitors, cultured ex-vivo — The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitors (HTLP)) injection to accelerate immune reconstitution after haploidentical hematopoietic stem cell transplantation (HSCT) with post-transplant cyclophosphamide (PT-Cy) in adult patients with hematological malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Cannot have received: allogeneic stem cell transplantation
Cannot have received: cellular therapy
Cannot have received: investigational agent
Lab requirements
Kidney function
adequate renal function as assessed by standard laboratory criteria
Liver function
adequate hepatic function as assessed by standard laboratory criteria
Cardiac function
left ventricular ejection fraction of ≥40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05768035 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplantation, cellular therapy, investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify